查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018489

CBD消费者保健市场：按产品类型、剂型、大麻素频谱和应用划分－2026-2032年全球市场预测

CBD Consumer Health Market by Product Type, Dosage Form, Cannabinoid Spectrum, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，CBD 消费者保健市场价值将达到 143.9 亿美元，到 2026 年将成长至 166.2 亿美元，到 2032 年将达到 415.6 亿美元，复合年增长率为 16.35%。

主要市场统计数据
基准年 2025 143.9亿美元
预计年份：2026年 166.2亿美元
预测年份 2032 415.6亿美元
复合年增长率 (%) 16.35%

消费者 CBD 保健市场的最新发展，重点关注市场成熟度、对科学证据的期望、监管压力以及对策略规划的影响。

受社会对植物来源治疗方法认知度提升和对传统药物替代品需求成长的推动，CBD保健品市场已从小众领域发展成为注重健康的消费者的主流选择。近年来，产品创新和零售网路的拓展，使CBD产品得以进入药局商店、专业健康零售商以及以数位化为主导的D2C（直接面向消费者）通路。同时，不断深入的科学研究和临床应用，增强了消费者对特定适应症的信心，并促使消费者形成更成熟的购买流程，将临床疗效与生活方式定位相结合。

产品创新、监管变化和不断提高的消费者期望如何重新定义竞争优势和业务重点。

三大相互关联的因素正在重塑CBD市场格局：加速的产品创新拓宽了CBD消费和体验方式；监管法规的修订限制并明确了允许的活动；以及不断提高的临床和品质证据标准，使普通商品与值得信赖的品牌区分开来。这些因素相互促进。随着监管法规的日益清晰，大型零售商和机构投资者对CBD产品的信心增强，刺激了资本流入，用于扩大规模和加大研发投入以验证其功效。因此，CBD市场正从早期实验阶段迈向一个以卓越营运和对监管法规的深刻理解为驱动差异化的阶段。

到 2025 年的关税措施正在重组供应链，加速近岸外包和垂直整合，并再形成整个生态系统的筹资策略。

近期推出的关税措施增加了此类供应链的复杂性，促使企业重新评估其筹资策略和服务交付成本。进口关税及相关贸易措施凸显了投资近岸外包和国内加工的重要性，因为企业力求保护其毛利率免受跨境成本不可预测波动的影响。为此，采购团队正在扩大供应商组合，并提高库存可见性，以降低关税突然上涨的风险。因此，随着企业在柔软性和可预测性之间寻求平衡，长期合约和策略供应商伙伴关係正变得越来越普遍。

细分市场分析揭示了产品形式和治疗应用在哪些方面创造了高端定位和实证差异化的机会。

检验产品类型进行细分，可以清楚了解消费者的需求和创新路径。胶囊和软胶囊因其隐藏性、精确的剂量以及与日常补充剂搭配的兼容性而备受消费者青睐。同时，油剂和酊剂仍然受到重视剂量控制和配方透明度的使用者的青睐。烘焙点心、糖果甜点、饮料和软糖等食用产品凭藉其便利性和美味性而日益受到欢迎，但要保持消费者的信任，严格的标籤和剂量一致性至关重要。外用製剂，包括膏霜、软膏、乳霜、乳液和贴片等子类别，越来越多地被定位在疼痛管理和个人护理领域，配方稳定性和给药技术在这些领域至关重要。电子烟产品，包括烟弹和电子烟笔，仍然是一个小众管道，但由于吸入风险，其受到越来越多的监管关注，这促使一些老牌公司优先考虑非吸入给药系统，并减少对这一渠道的投入。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势决定了监管风险、通路成熟度和市场准入要求。

在美洲，我们看到的是一个异质性强但日益制度化的市场结构，联邦监管的模糊性与州和地方层级健全的监管框架并存。这既带来了机会，也带来了挑战。本土品牌可以利用强大的零售网路和消费者熟悉度，同时应对各州不同的法规要求和不断变化的标籤标准。在这种环境下，常见的策略性应对措施包括与全国性零售商合作、投资合规团队以及製定针对各州的打入市场策略策略。

主要企业和新兴企业如何透过证据产生、供应链信任和策略管道多元化来建立竞争优势。

主要企业正透过整合证据产生、供应链透明度和通路多元化来脱颖而出。其策略重点包括投资第三方检测和追溯系统以支援产品声明，建立临床伙伴关係以产生可靠的疗效数据，以及拓展至重视更高品质保证的药房和医疗保健专业人员推荐管道。同时，敏捷的新兴企业则专注于特定应用和管理系统，利用直接面向消费者 (D2C) 的营销方式建立强大的品牌忠诚度，并采用敏捷的产品开发週期快速响应消费者反馈，从而追求细分市场的领先地位。

面对不断变化的法规环境，经营团队需要采取切实可行的短期和中期优先事项，以增强韧性、展现成效并调整供应链和通路策略。

首先，为了赢得监管机构和消费者的信任，应优先投资于检验的品质系统和透明的供应链实践。这包括标准化的第三方检测、批次追溯以及公开的采购和生产流程文件。中期来看，这些投资将减少与主要零售客户的摩擦，并支持高端定价策略。其次，产品系列应与差异化的证据策略一致。临床和真实世界证据资源应分配到那些检验可能取得成效的领域，例如疼痛管理和某些神经系统疾病，同时利用消费者研究来优化面向生活方式细分市场的配方，例如个人护理和睡眠支持。

结合一手访谈、消费者调查、监管分析和检验的混合研究框架，可以产生检验且可操作的见解。

本调查方法整合了来自一手和二手调查的数据，建构了该品类稳健、全面且整体情况。一手调查包括对供应链负责人、零售和药房管道的高级品类采购员、产品开发主管以及临床顾问进行结构化检验，以了解决策因素和营运限制。同时，消费行为研究深入分析了目标受众的购买动机、产品认知和未满足的需求。二手调查系统地考察了监管出版刊物、公开的临床文献、专利趋势和零售品类分析，以了解市场动态和监管趋势的背景。

策略整合提取监管压力、关税波动和特定领域的证据要求如何驱动合规、供应和商业化方面的综合决策。

总而言之，CBD消费保健品领域正朝着更制度化、对证据要求更高以及商业模式更加成熟的方向发展。监管趋势和关税压力正在重塑供应链，推动企业投资近岸外包和垂直整合。同时，市场细分洞察为差异化提供了清晰的方向。在某些产品类型和治疗应用领域，严格的临床检验和配方设计至关重要；而在其他领域，品牌塑造和感官创新则更具优势。从地理角度来看，企业要实现永续成长，需要将全球品质标准与当地法规和文化差异相协调。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：CBD消费者保健市场：依产品类型划分

  • 胶囊和软胶囊
  • 食用产品
    • 烘焙点心和糖果甜点
    • 饮料
    • 软糖
  • 油和酊剂
  • 外用製剂
    • 药膏/软膏
    • 乳霜和乳液
    • 修补
  • 电子烟产品
    • 墨水匣
    • 电子烟笔

第九章：以剂型分類的CBD消费者保健市场

  • 口服
  • 外用
    • 乳霜和乳液
    • 药膏和软膏
    • 修补
  • 吸入
  • 黏膜吸收

第十章：以大麻素频谱分類的CBD消费者保健市场

  • 全光谱
  • 频谱
  • CBD隔离群
  • 次要大麻素优势

第十一章：CBD消费者保健市场：依应用领域划分

  • 焦虑和压力
  • 神经系统疾病
  • 疼痛管理
  • 个人护理和化妆品
  • 睡眠障碍

第十二章：CBD消费者保健市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：CBD消费者保健市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：CBD消费者保健市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国CBD消费者保健市场

第十六章：中国CBD消费保健市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurora Cannabis Inc.
  • Bluebird Botanicals, LLC
  • CANNA LIFESTYLE Ltd.
  • Canopy Growth Corporation
  • CBDfx LLC
  • CBDistillery, LLC
  • cbdMD, Inc.
  • Charlotte's Web Holdings, Inc.
  • CV Sciences, Inc.
  • Diamond CBD, LLC
  • DSM-Firmenich
  • Endoca Holland BV
  • General Cannabis Corp.
  • Green Roads Health, LLC
  • HempFusion Wellness, Inc.
  • HempHeros, LLC
  • HempLife Today, Inc.
  • Joy Organics, Inc.
  • Lazarus Naturals, LLC
  • Medical Cannabis, Inc.
  • Medterra CBD LLC
  • PharmaHemp doo
  • PlusCBD Oil, Inc.
  • Social CBD, Inc.
Product Code: MRR-A339DAEFA242

The CBD Consumer Health Market was valued at USD 14.39 billion in 2025 and is projected to grow to USD 16.62 billion in 2026, with a CAGR of 16.35%, reaching USD 41.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.39 billion
Estimated Year [2026] USD 16.62 billion
Forecast Year [2032] USD 41.56 billion
CAGR (%) 16.35%

A contemporary orientation to the consumer CBD health market highlighting market maturity, evidence expectations, regulatory pressures, and implications for strategic planning

The consumer CBD health category has matured from niche curiosity to a mainstream consideration among health-conscious consumers, catalyzed by shifting societal attitudes toward plant-based therapeutics and a growing appetite for alternatives to traditional pharmaceuticals. Over the past several years, product innovation and retail expansion have broadened the category's footprint across pharmacy counters, specialty wellness retailers, and digital-first direct-to-consumer channels. At the same time, scientific inquiry and clinical interest have elevated credibility for targeted indications, prompting more sophisticated buyer journeys that combine clinical claims with lifestyle positioning.

Meanwhile, policy and regulatory frameworks continue to shape what is permissible in labeling, distribution, and marketing, which in turn influence product design and corporate compliance models. As a result, commercial leaders are balancing rapid commercial experimentation with risk-aware approaches to claims, testing, and supply chain transparency. Consequently, companies that can demonstrate rigorous quality controls, credible evidence, and clear messaging are better positioned to win the trust of both consumers and channel partners.

The remainder of this executive summary will unpack the transformative shifts in the landscape, assess the cumulative effects of recent tariff actions, surface nuanced segmentation insights, highlight regional patterns and competitive behaviors, and conclude with pragmatic recommendations for leaders seeking to convert insight into action.

How product innovation, regulatory recalibration, and rising consumer expectations are converging to reset competitive advantage and operational priorities

The landscape has been reshaped by three interlocking forces: accelerated product innovation that expands how CBD is delivered and experienced, regulatory recalibration that constrains and clarifies permissible activity, and a rising standard of clinical and quality evidence that separates commodity offerings from trusted brands. These forces are reinforcing each other; as regulations clarify, larger retailers and institutional buyers gain confidence to list products, prompting more capital to pursue scale and more rigorous R&D investments to validate claims. Consequently, the category is moving from early-stage experimentation to a phase where operational excellence and regulatory literacy drive differentiation.

Concurrently, consumer sophistication is rising. Early adopters prioritized novelty, but mainstream buyers evaluate efficacy, sourcing transparency, and third-party testing information during purchase. This shift incentivizes brands to invest in clinical collaborations, real-world evidence collection, and supply chain traceability. Retailers are responding by tightening onboarding criteria and demanding robust certifications, which increases barriers to entry for low-quality manufacturers while rewarding firms that excel in quality assurance and documentation.

Finally, distribution models are evolving. Digital channels continue to be an important growth vector, but omnichannel strategies that combine e-commerce precision with in-store education and sampling are gaining traction. In sum, these transformative shifts favor organizations that can synchronize product innovation with compliance frameworks, evidence generation, and an omnichannel go-to-market approach.

How tariff actions through 2025 are reconfiguring supply chains, accelerating nearshoring and vertical integration, and reshaping procurement strategies across the ecosystem

Recent tariff actions have introduced a new layer of complexity into the category's supply chains, prompting companies to reassess sourcing strategies and cost-to-serve calculations. Import duties and related trade measures have elevated the importance of nearshoring and domestic processing investments as firms seek to insulate gross margins from unpredictable cross-border cost shocks. In response, procurement teams are diversifying supplier portfolios and increasing inventory visibility to reduce exposure to sudden duty increases. Consequently, long-term contracting and strategic supplier partnerships have become more common as firms trade off flexibility for predictability.

These tariff-driven pressures have also accelerated interest in vertical integration, with some manufacturers exploring ownership stakes in extraction and formulation assets to secure input quality while buffering against external price volatility. Meanwhile, brands that rely on imported finished goods are recalibrating channel strategies, shifting to higher-value offerings and emphasizing traceability and certification as a way to justify premium positioning. At the same time, smaller brands facing tightened margins are increasingly forming alliances with co-manufacturers or pursuing licensing arrangements to maintain market presence without absorbing the full capital burden of reshoring.

In total, tariffs have nudged the ecosystem toward greater supply chain resilience and strategic localization, while simultaneously driving innovation in procurement, contract structuring, and manufacturing partnerships that will shape competitive positioning beyond the immediate policy cycle.

Segment-level analysis revealing where product formats and therapeutic applications create opportunities for premium positioning and evidence-based differentiation

Examining product-type segmentation reveals distinct consumer needs and innovation pathways. Capsules and softgels attract consumers seeking discrete, measured dosing and compatibility with daily supplement routines, while oils and tinctures continue to serve users focused on dose control and formulation transparency. Edibles, including baked goods and confectionery, beverages, and gummies, have expanded accessibility and flavor-driven appeal, but they also demand rigorous labeling and dosing consistency to preserve consumer trust. Topicals, with subcategories such as balms and salves, creams and lotions, and patches, are increasingly positioned within pain management and personal care contexts where formulation stability and delivery technology matter. Vape products, divided into cartridges and vape pens, remain a niche channel with heightened regulatory attention due to inhalation concerns, which has pushed some incumbents to deprioritize this route in favor of non-inhalation delivery systems.

Application-based segmentation further clarifies where clinical evidence and tailored formulations can unlock premium positioning. Anxiety and stress applications, from general anxiety management to PTSD-focused formulations, require careful claim language and often benefit from clinical or real-world evidence to support efficacy. Neurological disorder applications, such as epilepsy and multiple sclerosis, are anchored by clinical precedent and therefore demand rigorous sourcing and regulatory alignment. Pain management spans arthritis, muscle aches and pains, and neuropathic pain, signaling that topical innovation, targeted delivery, and cross-modal strategies combining oral and topical approaches are key differentiators. Personal care and cosmetics, including hair care and skincare, offer a bridge to mainstream beauty channels but require clear safety and dermatological testing. Sleep disorder applications, covering insomnia and sleep apnea-related management strategies, spotlight formulations and delivery profiles that prioritize sustained-release and interaction with existing sleep therapeutics.

Taken together, these segmentation patterns indicate that product development and evidence-generation strategies should be tailored to the specific regulatory sensitivities and clinical expectations of each subsegment, while commercial strategies must align channel choice with user behavior and therapeutic intent.

Regional patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory risk, channel maturity, and market entry imperatives

The Americas exhibit a heterogeneous but increasingly institutionalized market structure where regulatory ambiguity at the federal level coexists with robust state and provincial frameworks. This creates both opportunity and complexity: domestic brands can leverage strong retail networks and consumer familiarity, yet they must navigate a patchwork of state-level requirements and evolving labeling norms. In such an environment, partnerships with national retailers, investment in compliance teams, and state-specific go-to-market playbooks are common strategic responses.

In Europe, the Middle East & Africa, regulatory frameworks are progressively harmonizing around safety standards and novel-food pathways, though national interpretations still vary. Consumer awareness is rising across several European markets, driving demand for clinically supported products and pharmaceutical-grade manufacturing practices. At the same time, evolving import and certification requirements necessitate careful regulatory intelligence and local market entry strategies, particularly for suppliers aiming to serve both Western European discretionary buyers and emerging market consumers seeking value propositions.

Asia-Pacific reflects a spectrum of maturity levels, from highly regulated markets that restrict certain cannabinoid products to more permissive jurisdictions experimenting with medical and wellness applications. In mature urban centers, premiumization and scientific validation are becoming central to winning consumer trust, while in other markets, affordability and distribution partnerships with established FMCG channels drive penetration. Across the region, cultural attitudes toward botanical therapies and the structure of healthcare systems will dictate whether CBD products align more closely with mainstream wellness, pharmaceutical channels, or niche specialty retailers.

Across regions, global players must blend centralized quality and evidence standards with decentralized regulatory and commercial execution to capture cross-border opportunities while mitigating legal and reputational risk.

How leading and emerging companies are building competitive advantage through evidence generation, supply chain trust, and strategic channel diversification

Leading companies are differentiating through a blend of evidence generation, supply chain transparency, and channel diversification. Strategic priorities include investing in third-party testing and traceability systems to validate product claims, forging clinical partnerships to produce credible efficacy data, and expanding into pharmacy and clinician-recommended channels that reward higher levels of quality assurance. At the same time, nimble challengers are pursuing niche leadership by focusing on specific applications or delivery systems, leveraging direct-to-consumer marketing to build meaningful brand loyalty, and using agile product development cycles to respond rapidly to consumer feedback.

Mergers, strategic alliances, and licensing arrangements are common mechanisms for accelerating capability build-out without overextending balance sheets. Companies that combine manufacturing strength with strong marketing and regulatory affairs teams tend to scale more sustainably, while those that neglect any one dimension-be it quality control, clinical validation, or channel access-face elevated commercial risk. Moreover, investor interest has shifted toward businesses that can demonstrate repeat purchase behavior, distribution stickiness, and a credible plan for navigating regulatory scrutiny, which reinforces a discipline around unit economics and customer lifetime value.

Overall, competitive advantage is increasingly a function of integrated capability across science, compliance, and commercialization, rather than purely distributional breadth or short-term promotional activity.

Actionable short- and medium-term priorities for executives to build resilience, prove efficacy, and align supply chain and channel strategies amid regulatory change

First, prioritize investment in verifiable quality systems and transparent supply chain practices to establish trust with both regulators and consumers. This includes standardized third-party testing, batch traceability, and publicly accessible documentation of sourcing and manufacturing practices. In the medium term, such investments reduce friction with large retail customers and support premium pricing strategies. Second, align product portfolios with differentiated evidence strategies: allocate clinical and real-world evidence resources to the applications most likely to reward validation, such as pain management and certain neurological indications, while using consumer research to optimize formulations for more lifestyle-oriented segments like personal care and sleep support.

Third, re-evaluate manufacturing footprint in light of tariff and trade volatility by exploring nearshoring, long-term supply agreements, or contracted manufacturing options that preserve margin and service levels. Fourth, diversify channel strategies to balance direct-to-consumer analytics with the credibility benefits of pharmacy and clinician channels; tailored merchandising, training, and clinician education programs frequently unlock high-value partnerships. Finally, embed scenario planning into strategic reviews so that regulatory shifts, tariff changes, or new clinical findings can be stress-tested against commercial plans and investment roadmaps. Taken together, these actions will help organizations convert insight into defensible market positions and operational resilience.

A mixed-methods research framework combining primary interviews, consumer studies, regulatory analysis, and triangulation to produce validated, actionable insights

The research methodology combined primary and secondary evidence streams to create a robust, triangulated view of the category. Primary research included structured interviews with supply chain leaders, senior category buyers across retail and pharmacy channels, product development executives, and clinical advisors to capture decision drivers and operational constraints. In parallel, consumer behavior studies provided qualitative depth on purchase motivations, product perceptions, and unmet needs among target cohorts. Secondary research comprised a systematic review of regulatory publications, public clinical literature, patent landscapes, and retail assortment analyses to contextualize market dynamics and regulatory trajectories.

To ensure validity, findings from different sources were cross-checked and reconciled: procurement claims were compared with observable trade and supplier patterns, clinical assertions were evaluated against peer-reviewed literature, and retail positioning was validated through mystery shopping and e-commerce assortment audits. Limitations were explicitly acknowledged where public data is sparse or regulatory opacity persists, and sensitivity checks were performed to identify which conclusions were most susceptible to changing policy or trade conditions. This mixed-methods approach delivers actionable insights while transparently flagging areas where additional primary data collection would further reduce uncertainty.

A strategic synthesis that distills how regulatory pressure, tariff shifts, and segment-specific evidence requirements should drive integrated decisions across compliance, supply and commercialization

In synthesis, the consumer CBD health category is evolving toward greater institutionalization, higher evidence expectations, and more sophisticated commercial models. Regulatory dynamics and tariff pressures are restructuring supply chains and prompting investments in nearshoring and vertical integration. At the same time, segmentation insights reveal clear vectors for differentiation: certain product types and therapeutic applications reward clinical validation and formulation rigor, while others benefit from branding and sensory innovation. Regionally, companies must align global quality standards with local regulatory and cultural nuances to unlock durable growth.

For leaders, the implication is clear: success will require integrated capabilities across compliance, clinical evidence, supply chain resilience, and channel strategy. Those who act proactively-strengthening quality systems, targeting evidence generation to high-value applications, and adapting manufacturing footprint to trade realities-will be better positioned to convert regulatory and market disruptions into competitive advantage. As a next step, organizations should translate these insights into concrete investment and operating plans that prioritize both short-term resilience and long-term brand credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CBD Consumer Health Market, by Product Type

  • 8.1. Capsules & Softgels
  • 8.2. Edibles
    • 8.2.1. Baked Goods & Confectionery
    • 8.2.2. Beverages
    • 8.2.3. Gummies
  • 8.3. Oils & Tinctures
  • 8.4. Topicals
    • 8.4.1. Balms & Salves
    • 8.4.2. Creams & Lotions
    • 8.4.3. Patches
  • 8.5. Vape Products
    • 8.5.1. Cartridges
    • 8.5.2. Vape Pens

9. CBD Consumer Health Market, by Dosage Form

  • 9.1. Oral
  • 9.2. Topical
    • 9.2.1. Creams And Lotions
    • 9.2.2. Balms And Salves
    • 9.2.3. Patches
  • 9.3. Inhalation
  • 9.4. Transmucosal

10. CBD Consumer Health Market, by Cannabinoid Spectrum

  • 10.1. Full Spectrum
  • 10.2. Broad Spectrum
  • 10.3. CBD Isolate
  • 10.4. Minor Cannabinoid Dominant

11. CBD Consumer Health Market, by Application

  • 11.1. Anxiety & Stress
  • 11.2. Neurological Disorders
  • 11.3. Pain Management
  • 11.4. Personal Care & Cosmetics
  • 11.5. Sleep Disorders

12. CBD Consumer Health Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CBD Consumer Health Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CBD Consumer Health Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States CBD Consumer Health Market

16. China CBD Consumer Health Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aurora Cannabis Inc.
  • 17.6. Bluebird Botanicals, LLC
  • 17.7. CANNA LIFESTYLE Ltd.
  • 17.8. Canopy Growth Corporation
  • 17.9. CBDfx LLC
  • 17.10. CBDistillery, LLC
  • 17.11. cbdMD, Inc.
  • 17.12. Charlotte's Web Holdings, Inc.
  • 17.13. CV Sciences, Inc.
  • 17.14. Diamond CBD, LLC
  • 17.15. DSM-Firmenich
  • 17.16. Endoca Holland B.V.
  • 17.17. General Cannabis Corp.
  • 17.18. Green Roads Health, LLC
  • 17.19. HempFusion Wellness, Inc.
  • 17.20. HempHeros, LLC
  • 17.21. HempLife Today, Inc.
  • 17.22. Joy Organics, Inc.
  • 17.23. Lazarus Naturals, LLC
  • 17.24. Medical Cannabis, Inc.
  • 17.25. Medterra CBD LLC
  • 17.26. PharmaHemp d.o.o.
  • 17.27. PlusCBD Oil, Inc.
  • 17.28. Social CBD, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CBD CONSUMER HEALTH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CBD CONSUMER HEALTH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS AND LOTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS AND LOTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS AND LOTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS AND SALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS AND SALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS AND SALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TRANSMUCOSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TRANSMUCOSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TRANSMUCOSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY FULL SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY FULL SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY FULL SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BROAD SPECTRUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BROAD SPECTRUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BROAD SPECTRUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CBD ISOLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CBD ISOLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CBD ISOLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MINOR CANNABINOID DOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MINOR CANNABINOID DOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MINOR CANNABINOID DOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY CANNABINOID SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)